Arnold&Porter

EU Annual Life Sciences Conference

Agenda 5th March 2020

Time	Title	Speaker (s)
8.30 - 8.55	Registration	
9 - 9.40 (40 mins)	 Update on pricing and reimbursement in the UK & EU First year of the Voluntary Pricing and Access Scheme (VPAS) Access to treatments for rare diseases and recent challenges against negative funding decisions Update in NHS England's new commercial framework 	Adela Williams
9.40 - 10.25 (45 mins)	Cell & Gene Therapy • Standardisation • Market Access • Collaborations	Lincoln Tsang Ewan Townsend Beatriz San Martin
10.25 - 10.55 (30 mins)	Morning break	
10.55 - 12.15 (80 mins)	 Regulatory Update Recent case law in relation to parallel trade Duplicate marketing authorisations Update on off-label and unlicensed use of medicinal products Access to documents and the European Court's recent decisions in MSD Animal Health and PTC Therapeutics International. Ratiopharm v Novartis Consumer Health - provision of samples Bioplus Life Sciences and others v Secretary of State for Health - damages relating to unlicensed supply of competitor products 	Ian Dodds-Smith Adela Williams Alexander Roussanov Libby Amos Louise Strom
12.15 - 12.35 (20 mins)	 Considerations in drafting arbitration clauses for commercial contracts Choosing the arbitral "seat" Selecting the arbitration rules The perils of over-complication 	Monty Taylor
12.35 - 1.35 (1 hour)	Lunch	
1.35 - 2.20 (45 mins)	Al and mhealth: an Al medical device case study Challenges for: IP Regulatory Privacy Product liability	Tom Fox Beatriz San Martin Alexander Roussanov
2.20 - 3.00 (40 mins)	 Competition law update Restrictive Agreements: The Aspen and Tiofarm settlements with the CMA Excessive pricing: The Pfizer/Flynn appeal Market definition: Molecule vs ATC3? Paroxetine vs Perindopril Brexit, what Brexit? 	John Schmidt
3.00 - 3.30 (30 mins)	Afternoon break	
3.30 - 4.00 (30 mins)	Update on the implementation of the MDR & IVDR	Lincoln Tsang Louise Strom
4.00 - 4.30 (30 mins)	 Dispelling the myths of access to Cannabis products Supply of unlicensed medicines and novel foods containing cannabis Enforcement trends 	Sean Curran Libby Amos
	Drinks reception	

DYS DY